Kyle Faget Authors Article on Considerations for Mobile Health Technology Developers
28 September 2022
Foley & Lardner LLP Partner Kyle Faget authored the article, “Considerations for Mobile Health Technology Developers: Part 1,” published by pharmaphorum, about the U.S. Food and Drug Administration (FDA)’s common approach to regulating mHealth products, general wellness devices, and mobile medical applications.
Faget says, “Although mHealth has been gaining in popularity for at least the past decade, before commercializing their mHealth products, developers must determine whether the product is subject to (FDA) regulation as a medical device. If so, developers must develop and execute on a regulatory strategy.”
Part 2 of this series will be devoted to clinical decision support (CDS) software.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”